Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 21, 2008, Keryx Biopharmaceuticals, Inc. (the "Company") issued a press release announcing that on November 17, 2008, it received notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company is no longer in compliance with Nasdaq Marketplace Rule 4310(c)(3). The press release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference. Additionally, a copy of the letter from The Nasdaq Stock Market is being furnished as Exhibit 99.2 to this report.

---